Drug Resistance, Viral

"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.

Descriptor ID	D024882
MeSH Number(s)	G06.225.420 G06.920.225 G07.690.773.984.269.420
Concept/Terms	Drug Resistance, Viral Drug Resistance, Viral Drug Resistances, Viral Antiviral Drug Resistance Antiviral Drug Resistances

Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".

Biological Sciences [G]
Microbiological Phenomena [G06]
Drug Resistance, Microbial [G06.225]
Drug Resistance, Viral [G06.225.420]
Virus Physiological Phenomena [G06.920]
Drug Resistance, Viral [G06.920.225]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Drug Resistance [G07.690.773.984]
Drug Resistance, Microbial [G07.690.773.984.269]
Drug Resistance, Viral [G07.690.773.984.269.420]

Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".

Drug Resistance, Viral
Drug Resistance, Multiple, Viral

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.

Bar chart showing 84 publications over 24 distinct years, with a maximum of 8 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	1	2
2003	1	3	4
2004	1	3	4
2005	1	1	2
2006	2	2	4
2007	1	1	2
2008	2	1	3
2009	1	3	4
2010	4	4	8
2011	2	2	4
2012	6	0	6
2013	4	2	6
2014	4	1	5
2015	2	0	2
2016	2	2	4
2017	0	1	1
2018	1	1	2
2019	4	2	6
2020	2	0	2
2021	0	3	3
2022	2	0	2
2023	0	1	1
2024	2	0	2
2025	4	1	5

Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.

Kaur J, Spielvogel E, Nageswara Rao D, Rusere LN, Shaqra AM, Lockbaum GJ, Maryam A, Yilmaz NK, Swanstrom R, Schiffer CA, Ali A. Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2' ligands with potent activity against drug-resistant variants. Eur J Med Chem. 2026 Feb 15; 304:118510.

View in: PubMed
Intravaia LE, Shaqra AM, Pirhadi S, Popko N, Kurt Yilmaz N, Schiffer CA. Predicting the Impact of Drug Resistance Mutations on Inhibitor Potency with Molecular Dynamics and Machine Learning. J Phys Chem B. 2025 10 30; 129(43):11128-11140.

View in: PubMed
Zvornicanin SN, Shaqra AM, Flynn J, Carias Martinez H, Jia W, Moquin S, Dovala D, Bolon DN, Kurt Yilmaz N, Schiffer CA. Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50. mBio. 2025 05 14; 16(5):e0406824.

View in: PubMed
Azzolino VN, Shaqra AM, Ali A, Kurt Yilmaz N, Schiffer CA. Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease. Viruses. 2025 01 08; 17(1).

View in: PubMed
Ngo HHT, Pham TPT, Hoang HTT, Bui DH, Phan HTT, Nguyen QC, Duong TC, Bui HT, Nguyen HTT, Le MQT, Dang AD, McFarland W, Truong HM, Pham TH. Detection of Antiretroviral Drug-Resistant Mutations and HIV-1 Subtypes in Circulation Among Men Who Have Sex With Men, SEM Females, and Female Sex Workers: Results of Vietnam's HIV Sentinel Surveillance Plus System, 2018-2020. J Acquir Immune Defic Syndr. 2025 01 01; 98(1):29-36.

View in: PubMed
Azzolino VN, Shaqra AM, Ali A, Kurt Yilmaz N, Schiffer CA. Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance. Viruses. 2024 09 05; 16(9).

View in: PubMed
Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, Boucau J, Glover OT, Barry M, Gilbert RF, Reynolds Z, Li Y, Tien D, Vyas TD, Passell E, Su K, Drapkin S, Abar EG, Kawano Y, Sparks JA, Wallace ZS, Vyas JM, Shafer RW, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024 09 03; 7(9):e2435431.

View in: PubMed
Spielvogel E, Lee SK, Zhou S, Lockbaum GJ, Henes M, Sondgeroth A, Kosovrasti K, Nalivaika EA, Ali A, Yilmaz NK, Schiffer CA, Swanstrom R. Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance. Elife. 2023 03 15; 12.

View in: PubMed
Zephyr J, Nageswara Rao D, Vo SV, Henes M, Kosovrasti K, Matthew AN, Hedger AK, Timm J, Chan ET, Ali A, Kurt Yilmaz N, Schiffer CA. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. J Mol Biol. 2022 05 15; 434(9):167503.

View in: PubMed
Jiang L, Samant N, Liu P, Somasundaran M, Jensen JD, Marasco WA, Kowalik TF, Schiffer CA, Finberg RW, Wang JP, Bolon DNA. Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y. J Virol. 2022 03 23; 96(6):e0198221.

View in: PubMed

People

Explore

Similar Concepts

Top Journals